Anti-inhibitory coagulant complex - instructions for use, doses, side effects, contraindications

Clinical and pharmacological group: & nbsp

Coagulants (including clotting factors), hemostatics

Included in the formulation

Feiba®

lyophilizate d / infusion

Baxter AG Austria

Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

ONLS

АТХ:

B.02.B.D Coagulation factors

Pharmacodynamics:

Prevents the effect of inhibitors on the VIII factor of blood coagulation. Inhibition of inhibitors leads to the normalization of hemostasis.

Pharmacokinetics:

Not studied.

Indications:

It is used for the prevention and treatment of bleeding in patients with an inhibitory form of hemophilia A and B, as well as in patients with acquired coagulopathies for VIII, XI and XII blood clotting factors.

ICD-10

III.D65-D69.D66 Hereditary deficiency of factor VIII

III.D65-D69.D67 Hereditary deficiency of factor IX

III.D65-D69.D68.4 Acquired Coagulation Factor Deficiency

Contraindications:

Syndrome of disseminated intravascular coagulation, thromboembolism, myocardial infarction.

Individual intolerance.

Carefully:

It is used with caution in liver failure, signs of fibrinolysis and a tendency to thrombosis.

Pregnancy and lactation:

Pregnancy and lactation: recommendations for Food and Drug Administration (US Food and Drug Administration) - safety for pregnant and lactating women is not defined.The drug is used for life indications in cases when there are no alternative methods of treatment.

Dosing and Administration:

The drug is administered intravenously drip with an infusion rate of no more than 2 U / kg per minute.

Treatment is carried out under the control of a coagulogram.

The dose and duration of treatment depends on the clinical condition of the patient, the severity of hemostasis, intensity and localization of bleeding.

Hemarthroses: 50-75 U / kg with a 12-hour interval to clinical improvement - restoration of joint function, disappearance of pain and swelling.

Hematomas in soft tissues: 100 units / kg every 12 hours.

Bleeding from the mucous membranes: 50 units / kg every 6 hours, with insufficient effectiveness, the dose increases to 100 U / kg, but without exceeding the maximum daily dose (200 U / kg).

Extensive bleeding, including hemorrhages in the brain: 100 U / kg in 6-12 hours.

Prophylactic dose for hemophilia: 50-100 units / kg every 12 hours or a single dose of 50-100 units / kg 3 times a week.

The highest daily dose: 200 units / kg.

The highest single dose: 100 units / kg.

Side effects:

Excess of infusion speed leads to acute pain, numbness of face and limbs, hypotension.

Allergic reactions.

Overdose:

The syndrome of disseminated intravascularMyocardial infarction, thromboembolism.

Interaction:

It should be avoided mixing the drug with other medicines. Before the introduction of the drug and after - rinse the general venous access with saline.

Special instructions:

The solution of the preparation is prepared before the introduction, it is not subject to storage, since it does not contain preservatives. Unused solutions are disposed of according to the instructions.

Treatment with the drug provides for mandatory control of the coagulogram.

Instructions

Anti-inhibitory coagulant complex (Anti-inhibitor Coagulant Complex)